Release date: 2009-02-19
A groundbreaking "tumor gene chip diagnostic kit" has been successfully developed in Lanzhou, marking a significant step forward in early cancer detection and treatment in China. With an accuracy rate exceeding 95%, this innovative tool is set to revolutionize the way we approach cancer prevention and diagnosis. According to the Lanzhou Science and Technology Bureau, the "Oncology Gene Chip Diagnostic Kit," created by Professor Liu Jianyun from the Lanzhou Biochemical Engineering Technology Center, has received certification from the German National Genetic Laboratory and is now being used for preclinical diagnostic support.
The technology behind the tumor gene chip represents one of the most advanced methods currently available for accurate disease detection. By using cutting-edge liquid chip technology, it can precisely measure the levels of trace markers in different organs through blood samples, offering valuable insights for early cancer detection and risk assessment. Leveraging state-of-the-art SNP genotyping instruments and the Illumina platform, the system analyzes genetic data to generate personalized health reports that evaluate tumor-related genes and their impact on overall health. This allows individuals to gain a more accurate understanding of their cancer risk and take proactive steps to manage potential threats.
Professor Liu explained that genes are functional units of DNA responsible for transmitting hereditary information and determining life characteristics. These genetic codes, inherited from our parents at the moment of conception, play a crucial role in shaping our health. The tumor gene test involves collecting just 5 ml of peripheral blood from the individual, extracting and amplifying genetic material, and then analyzing it using a gene chip to identify any disease-associated genes. This process enables the detection of "gene mines" hidden within the body before symptoms appear.
After nearly three years of research and testing, the Tumor Gene Chip Diagnostic Kit has reached a mature stage and is now being applied in clinical settings. Since 2006, over 300 trials have been conducted across multiple institutions, including the Civil Aviation Medical Research Center in China, Peking University Hospital, and hospitals in Germany such as Hannover and Regensburg. The results showed a specificity above 80%, with a diagnostic accuracy of over 95% in Germany and more than 98% in Chinese trials. The kit has gained recognition from both domestic and international experts.
Recently, the Lanzhou Biochemical Engineering Technology Center signed a production agreement with Lanzhou Huazhi Laiwei Medical Equipment Co., Ltd., aiming to bring this high-tech diagnostic tool to market on a larger scale. This collaboration marks an important milestone in the commercialization of innovative medical technologies in China.
——Shanghai Medical Device Industry Association
Alcohol Corn Gluten Feed,Custom Corn Gluten Feeds,Corn Gluten Feed To Chickens,Nutritional Corn Gluten Feed
JILIN COFCO BIO-CHEM AND BIO-ENERGY MARKETING CO., LTD , https://www.cofco-biotech.com